AliveCor and OMRON Announce Global Strategic Alliance

AliveCor, a leader in personal ECG products, and OMRON Healthcare, Co., Ltd., a global leader in personal heart health and wellness technology, today announced a global, strategic alliance that combines AliveCor’s ECG technology with industry-leading blood pressure devices from OMRON to better serve customers and expand access to remote patient care.

AliveCor advises this partnership aligns with global trends to deploy non-invasive remote monitoring devices to facilitate patient monitoring while reducing patient and healthcare provider contact during the current pandemic.

“At AliveCor, we are committed to providing life-saving cardiological services to those who need them most. The scope, scale, and strategic importance of this transaction are unprecedented in our corporate history,” said AliveCor CEO Priya Abani. “OMRON’s enormous R&D and distribution resources will bring AliveCor technology to more markets and more end-users than ever before.”

The COVID-19 pandemic underscores the importance of telemedicine in how we care for ourselves and loved ones. Those with chronic illnesses, including heart disease, are at higher risk of infection. AliveCor and OMRON serve this vulnerable population every day by allowing patients to send personal health data to physicians without leaving their homes. The companies’ ability to provide innovative, medical-grade technologies at home offers peace of mind to their users.

“The integration of these complementary technologies allows us to expand the heart health data we provide our customers and physician partners for a more complete picture of a patient’s heart health,” said Isao Ogino, president, and CEO of OMRON Healthcare.  “Our mission is ‘going for zero’ heart attacks and strokes. It is a lofty goal and we have committed to combining forces with like-minded partners to achieve it. OMRON has already made important strides with AliveCor to advance our mission and this expansion of that collaboration, including the development of remote patient monitoring services, is a valuable boost to our growing healthcare portfolio.”

The first technology collaboration between the two companies is the FDA cleared, award-winning OMRON Complete. Introduced in 2019, Complete is the first blood pressure monitor with ECG capability in a single device. The companies expect this product to be the first in a line of integrated ECG and blood pressure devices making home heart care more accessible to consumers than ever before.

The companies also announced today the closing of an equity investment by OMRON Corporation (OMRON Healthcare’s parent company) in AliveCor.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”